

App No. 09/307 575
Filed dated Jun 19, 2006
Reply to Office action of Mar 23, 2006

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1 (currently amended) A diagnostic kit agent for detection of a human cancer cell that expresses glypican-1 at least one of human breast cancer and pancreatic cancer, comprising: a binding molecule selected from the group consisting of an antibody and an antibody fragment that binds to ~~one of~~ human glypican-1 ~~and to human syndecan-1~~, and optionally a reporting molecule attached to the binding molecule such that a detection method allows detection of the cancer by detection of the presence of the binding molecule via detection of the reporting molecule; and an information associated with the binding molecule that binding of the binding molecule to a cell is indicative of a human cancer cell that expresses glypican-1
- 2 (Original) The diagnostic agent of Claim 1, wherein the binding molecule comprises an antibody.
- 3 (currently amended) The diagnostic agent of Claim 2, wherein the antibody is used to detect glypican-1 ~~or syndecan-1~~ in a body fluid.
- 4 (currently amended) The diagnostic agent of Claim 2, wherein the antibody is used to image glypican-1 ~~or syndecan-1~~
- 5 (currently amended) A therapeutic kit composition comprising a therapeutic agent at a concentration effective to slow growth of ~~at least one of human breast cancer cells and pancreatic human cancer cells~~ identified to express glypican-1, wherein the agent comprises a molecule selected from the group consisting of an antibody and an antibody fragment that affects glypican-1 by one of binding to an extracellular region of human glypican-1, cleaving an extracellular region of human glypican-1, and suppressing expression of an extracellular region of human glypican-1, and an information associated with the molecule that binding of the binding molecule to the cancer cells slows growth of the cancer cells.

App. No. 09/807,575

Amended June 19, 2006

Replies to Office action of Mar. 23, 2006

- 6 (Previously presented) The composition of Claim 5, wherein the molecule comprises an antibody that binds to the extracellular region of glypican-1.
- 7 (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.
- 8 (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.
- 9 (Withdrawn) A method for diagnosing human cancer comprising the steps of contacting a molecule that binds to one of glypican-1 and syndecan-1 with either a body fluid or body tissue, and detecting the molecule bound to glypican-1 or to syndecan-1.
- 10 (Withdrawn) The method of Claim 9, wherein the binding molecule comprises an antibody.
- 11 (Withdrawn) The method of Claim 10, wherein the antibody is used to detect glypican-1 or syndecan-1 in a body fluid.
- 12 (Withdrawn) The method of Claim 10, wherein the antibody is used to image glypican-1 or syndecan-1.
- 13 (Withdrawn) A method of slowing growth of human cancer cells comprising administering a molecule that affects glypican-1 by one of binding to an extracellular region of glypican-1, cleaving an extracellular region of glypican-1 and suppressing expression of an extracellular region of glypican-1.
- 14 (Withdrawn) The method of Claim 13, wherein the molecule comprises an antibody that binds to the extracellular region of glypican-1.
- 15 (Withdrawn) The method of Claim 13, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.
- 16 (Withdrawn) The method of Claim 13, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.

USPTO
COMMUNICATIONS SECTION

-3-

App. No. 09/807,575
Filed dated Jun. 19, 2006
Reply to Office action of Mar. 23, 2006

- 17 (New) The diagnostic kit of claim 1 wherein the human cancer cell is a pancreatic cancer cell or a breast cancer cell.
- 18 (New) The therapeutic kit of claim 5 wherein the human cancer cells are pancreatic cancer cells or breast cancer cells.